Ralph DeFronzo, MD

Ralph DeFronzo, MD
 

Professor of Medicine
Chief of the Diabetes Division
The University of Texas Health Science Center at San Antonio
San Antonio, Texas

What pathophysiological and mechanistic factors associated with the GLP-1 agonist liraglutide might explain the reduction in overall mortality, MACE, and CV mortality reported in the LEADER trial? Video

What pathophysiological and mechanistic factors associated with the GLP-1 agonist liraglutide might explain the reduction in overall mortality, MACE, and CV mortality reported in the LEADER trial?

What pathophysiological and mechanistic factors associated with the GLP-1 agonist liraglutide might explain the reduction in overall mortality, MACE, and CV mortality reported in the LEADER trial?
Ralph DeFronzo, MD

Ralph DeFronzo, MD

Can you compare the results, time lines, and insights gleaned from the LEADER trial with liraglutide, a GLP-1 RA, to those reported for EMPA-REG, which evaluated an SGLT2 inhibitor on CV risk? Video

Can you compare the results, time lines, and insights gleaned from the LEADER trial with liraglutide, a GLP-1 RA, to those reported for EMPA-REG, which evaluated an SGLT2 inhibitor on CV risk?

Can you compare the results, time lines, and insights gleaned from the LEADER trial with liraglutide, a GLP-1 RA, to those reported for EMPA-REG, which evaluated the effectiveness and safety of an SGLT2 inhibitor on CV risk?
Ralph DeFronzo, MD

Ralph DeFronzo, MD

How might the results of LEADER impact the prioritization of GLP-1 RAs as foundational agents for T2D, either alone or in combination with SGLT2 inhibitors or long-acting basal insulin? Video

How might the results of LEADER impact the prioritization of GLP-1 RAs as foundational agents for T2D, either alone or in combination with SGLT2 inhibitors or long-acting basal insulin?

How might the results of LEADER impact the prioritization of GLP-1 RAs as foundational agents for T2D, either as stand-alone agents or in combination with SGLT2 inhibitors? Or with long-acting basal insulin?
Ralph DeFronzo, MD

Ralph DeFronzo, MD

How should the front-line clinician treating T2D patients translate the results of the LEADER trial into clinical practice? Have these results prioritized GLP-1 RAs in the T2D treatment pathway? Video

How should the front-line clinician treating T2D patients translate the results of the LEADER trial into clinical practice? Have these results prioritized GLP-1 RAs in the T2D treatment pathway?

How should the front-line clinician treating T2D patients translate the results of the LEADER trial into clinical practice? Have these results prioritized GLP-1 RAs in the T2D treatment pathway?
Ralph DeFronzo, MD

Ralph DeFronzo, MD

What dosing considerations should we keep in mind for liraglutide based on the results of the LEADER trial? And what are the implications for insulin-GLP-1 RA combination therapy? Video

What dosing considerations should we keep in mind for liraglutide based on the results of the LEADER trial? And what are the implications for insulin-GLP-1 RA combination therapy?

What dosing considerations should we keep in mind for liraglutide based on the results of the LEADER trial? And what are the implications for insulin-GLP-1 RA combination therapy?
Ralph DeFronzo, MD

Ralph DeFronzo, MD